This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

GDS International Announces "Industry Leader Of The Year" Award At Its Fourth Annual European Pharmaceutical Drug Discovery Summit

MILAN, December 4, 2012 /PRNewswire/ --

Last month, 55 of Europe's biggest players from across the pharmaceutical drug discovery sector convened for two-and-a-half days as they attended the most disruptive event of the year - GDS International 's fourth Next Generation Pharmaceutical Drug Discovery summit (NGP DD EU), held at the Meliá Milano Hotel, Milan, Italy.

Europe has been an enduring force in the pharmaceutical industry for decades. However, increased competition due in part to globalisation, economic recession and ICT advancements has levelled the playing field for drug discovery. Wise investment and innovative new technologies are subsequently proving key to staying ahead of competitors. With this in mind, GDS International has created an award to recognise exceptional talent within the sector.

Selected as the winners by a panel of 20 senior executives from the R&D functions of global biopharma companies, Paul O'Riordan - CEO of Synexa Life Sciences, and Henning Steinhagen - SVP Head of Global Drug Discovery for Grünenthal, emerged the winners of this year's "Industry Leader of the Year" award for their pioneering new practices within the industry.

Synexa was awarded the title for its industry-leading approach to providing biopharma clients with biomarker expertise, analysis and insight; whilst Grünenthal was selected for its reorganization and strategy implementation for global chemistry outsourcing, and creating a new biology platform directed to immuno-inflammatory research.

Synexa's CEO, Paul O'Riordan, said: "This award is a tremendous acknowledgment of the hard work we have put in over the past 10 years to develop a biomarker services offering that our clients find really useful. To be honoured in this way by the very clients we strive to satisfy is humbling and extremely rewarding. We will use this vote of confidence to continue pushing boundaries in both the science and business of biomarkers."

He continues: "I thought the conference was fantastic. I had some reservations, but the event well exceeded my expectations. The networking opportunities were invaluable - we met exactly the right people and a wide range of potential clients. These people seemed to really appreciate the opportunity to meet us too, which is not always the case at many conferences, and shows how well-selected they were."

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,810.06 +91.06 0.51%
S&P 500 2,063.50 +10.75 0.52%
NASDAQ 4,712.97 +11.1030 0.24%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs